Posters
« Back
TYMS Dysregulation is a Molecular Switch and Tumorigenic Driver in Early Breast Cancer
EP25561
TYMS Dysregulation is a Molecular Switch and Tumorigenic Driver in Early Breast Cancer
Submitted on 13 Feb 2017

Barry J Barclay PhD
Planet Biotechnologies Inc and SunHealthRx Inc
Poster Views: 573
View poster »
Poster Abstract
It is suggested here that genetic (BRCA1, BRCA2), nutritional (folate, B12 deficiency) and environmental factors (complex chemical mixtures) can interact to cause unrepairable DNA damage throughout the nuclear genomes (nDNAs) of replicating breast stem cells. In the mitochondrial genome (mtDNA) which has far less DNA repair capacity and many more targets, accumulated genetic lesions lower the efficiency of p53 mediated apoptotic clearance of damaged nDNA over time. Unrepaired nDNA damage and consequential chromosomal rearrangements near cytogenetic band 18p11.32 can result in permanent TYMS dysregulation initiating breast tumor formation and by acting as a molecular switch drive early disease progression . Genomic, epigenomic, apoptotic, metabolic and bioenergetic effects caused by TYMS dysregulation include:

1.) Greatly increased rates of mutagenesis clastogenesis and chaotic recombinagenesis resulting in ongoing nDNA genomic instability including point mutations, insertions, deletions, duplications, inversions, translocations, gene fusions and conversions.
2. Chronic global hypomethylation caused by shunting of folate away from S-adenosylmethionine (SAMe) biosynthesis by excess TYMS expression.
Ongoing biosynthesis of the angiogenic factors deoxyribose (dR) and deoxyribose-1-phosphate (dR-1-P) by catalysis of excess intracellular pools of dUMP (switch low) or dTMP (switch high).
3.) A shift from oxidative phosphorylation (OXPHOS) to glycolysis (the Warburg effect) caused by ongoing genetic damage to both mtDNA and nDNA.
4.) Generation of tumorigenic exosomes encoding TYMS on extrachromosomal elements including circles or palindromic hairpins.
5.) Ongoing telomere shortening generating cell lineages with altered chromosome number (aneuploidy).
6.) Continuous formation of regions of cell lethality (apoptosis/necrosis) within the tumor cell mass due to low TYMS expression.




1.) Disruptive environmental chemicals and cellular mechanisms that confer resistance to cell death. Narayanan KB, Ali M, Barclay BJ, et al Carcinogenesis. 2015 Jun;36 Suppl 1: S89-110. doi: 10.1093/carcin/bgv032. Review.
2.) Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead. Goodson WH 3rd, Lowe L, Carpenter DO, Gilbertson M, Manaf Ali A, Lopez de Cerain Salsamendi A, Lasfar A, Carnero A, Azqueta A, Amedei A, Charles AK, Collins AR, Ward A, Salzberg AC, Colacci A, Olsen AK, Berg A, Barclay BJ, et al Carcinogenesis. 2015 Jun;36 Suppl 1:S254-96. Doi: 10.1093/carcin/bgv039. Review.
Report abuse »
Questions
Ask the author a question about this poster.
Ask a Question »

Creative Commons

Related Posters


MODEL-AD: Bioinformatics and Data ManagementMODEL-AD: Bioinformatics and Data Management
Bruce Lamb1, Michael Sasner2, Andrew Saykin1, Lara Mangravite3, Gregory Carter2

MODEL-AD: The Disease Modeling Project
M.Sasner1, A. Oblak2, H. Williams1, G. Howell1, B.T. Lamb2 and the MODEL-AD consortium

MODEL-AD: Genetic models of late-onset Alzheimer’s disease
*A. OBLAK1,2, G. CARTER3, G. R. HOWELL3, B. LOGSDON4, L. MANGRAVITE4, K. NHO2, L. OMBERG4, K. D. ONOS3, V. PHILIP3, C. PREUSS3, S. J. SUKOFF RIZZO3, M. SASNER3, L. SHEN1,2, A. J. SAYKIN1,2, P. TERRITO1,2, A. UYAR3, H. WILLIAMS3, B. T. LAMB1,5

ESTUDIO ANALÍTICO DE LA CALIDAD Y VALORACION NUTRICIONAL DE LALECHE HUMANA DE LAS MADRES DONANTES EN LA ZONA NORTE DEL TOLIMA
Kevin Fernando Romero Acosta; Monica Patricia Osorio Tangarife; Guillermo Salamanca Grosso

Preclinical drug screening in new generation Alzheimer’s disease mouse models: The MODEL-AD Consortium Strategy
P.R. Territo1, S.J. Sukoff Rizzo2, K. Onos2, J.A. Meyer1, J. Peters1, S.C. Persohn1, B.R. McCarthy1, A.A. Riley1, S. Quinney1, D. Jones1, M. Sasner2, G. Howell2, H. Williams2, A.J. Oblak1, B.L. Lamb1 and the MODEL-AD consortium